Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Research output: Contribution to journalJournal articleResearchpeer-review

Intracoronary (IC) administration of abciximab may increase local drug levels by several orders of magnitude compared to intravenous (IV) treatment and may improve clinical outcomes in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In the absence of results from large multicenter, randomized trials, we performed a systematic review and meta-analysis of available studies comparing IC to IV abciximab in these patients.
Original languageEnglish
JournalJournal of Invasive Cardiology
Volume22
Issue number6
Pages (from-to)278-82
Number of pages5
ISSN1042-3931
Publication statusPublished - 1 Jun 2010

ID: 34077456